Study to sort people with Gaucher disease into groups
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at people with Gaucher disease (types I, II, or III) to better “group” patients for understanding and future research. If you (or your child) have confirmed Gaucher disease, you may be asked to share information and follow a study schedule.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Gaucher disease, types I, II, or III
- You (or your parent/guardian) can give written consent, and you can agree as well if your age allows
- You can follow the study visits and required study steps on schedule
- The study may also include already-deceased patients if the ethics team approves using existing data
- You should not have another major illness that is expected to limit life to less than 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an injection called LY-M001 for adults with Gaucher disease type I. The goal is to see if it can safely help replace the missing enzyme and improve symptoms.
This study measures inflammation and “oxidative stress” (cell stress caused by imbalance in the body) using blood biomarkers in adults with Gaucher disease. It may help researchers understand what’s happening in the body and how treatment status relates to these blood signals.
This study tests whether a new drug called VGN-R08b can safely help children with Type III Gaucher disease—a rare genetic disorder affecting the brain and body. The drug is being tested in children aged 2–17 who have already tried other treatments but still have neurological symptoms, particularly eye movement problems.
This study looks at how Gaucher disease affects patients’ daily life and health outcomes through a survey. Your answers could help improve future care and treatments by showing what outcomes matter most.
This study is designed to learn what happens over time in people who have Gaucher disease. It may help researchers understand the long-term effects of the condition and improve future care.
This study looks at MRI-based lab measurements (similar to a special type of scan) to find markers that reflect health in people with type 3 Gaucher disease. It may help researchers track the disease over time and improve future treatments.
Hear when a new Gaucher Disease, Type I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.